OcuCure Therapeutics, Inc.   Report issue

For profit Phase 2
Founded: Roanoke VA United States (2005)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2013
NCT01869933
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

oc-10x (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Retinopathy (Phase 2)

Retinal Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1